Literature DB >> 34907331

Optimizing immunotherapy for colorectal cancer.

Karuna Ganesh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34907331      PMCID: PMC9487162          DOI: 10.1038/s41575-021-00569-4

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   73.082


× No keyword cloud information.
  10 in total

1.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

Authors:  Thierry André; Kai-Keen Shiu; Tae Won Kim; Benny Vittrup Jensen; Lars Henrik Jensen; Cornelis Punt; Denis Smith; Rocio Garcia-Carbonero; Manuel Benavides; Peter Gibbs; Christelle de la Fouchardiere; Fernando Rivera; Elena Elez; Johanna Bendell; Dung T Le; Takayuki Yoshino; Eric Van Cutsem; Ping Yang; Mohammed Z H Farooqui; Patricia Marinello; Luis A Diaz
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

2.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

Review 3.  Immunotherapy in colorectal cancer: rationale, challenges and potential.

Authors:  Karuna Ganesh; Zsofia K Stadler; Andrea Cercek; Robin B Mendelsohn; Jinru Shia; Neil H Segal; Luis A Diaz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06       Impact factor: 46.802

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

5.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

6.  First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Authors:  Heinz-Josef Lenz; Eric Van Cutsem; Maria Luisa Limon; Ka Yeung Mark Wong; Alain Hendlisz; Massimo Aglietta; Pilar García-Alfonso; Bart Neyns; Gabriele Luppi; Dana B Cardin; Tomislav Dragovich; Usman Shah; Sandzhar Abdullaev; Joseph Gricar; Jean-Marie Ledeine; Michael James Overman; Sara Lonardi
Journal:  J Clin Oncol       Date:  2021-10-12       Impact factor: 44.544

7.  Spatially organized multicellular immune hubs in human colorectal cancer.

Authors:  Karin Pelka; Matan Hofree; Jonathan H Chen; Siranush Sarkizova; Joshua D Pirl; Vjola Jorgji; Alborz Bejnood; Danielle Dionne; William H Ge; Katherine H Xu; Sherry X Chao; Daniel R Zollinger; David J Lieb; Jason W Reeves; Christopher A Fuhrman; Margaret L Hoang; Toni Delorey; Lan T Nguyen; Julia Waldman; Max Klapholz; Isaac Wakiro; Ofir Cohen; Julian Albers; Christopher S Smillie; Michael S Cuoco; Jingyi Wu; Mei-Ju Su; Jason Yeung; Brinda Vijaykumar; Angela M Magnuson; Natasha Asinovski; Tabea Moll; Max N Goder-Reiser; Anise S Applebaum; Lauren K Brais; Laura K DelloStritto; Sarah L Denning; Susannah T Phillips; Emma K Hill; Julia K Meehan; Dennie T Frederick; Tatyana Sharova; Abhay Kanodia; Ellen Z Todres; Judit Jané-Valbuena; Moshe Biton; Benjamin Izar; Conner D Lambden; Thomas E Clancy; Ronald Bleday; Nelya Melnitchouk; Jennifer Irani; Hiroko Kunitake; David L Berger; Amitabh Srivastava; Jason L Hornick; Shuji Ogino; Asaf Rotem; Sébastien Vigneau; Bruce E Johnson; Ryan B Corcoran; Arlene H Sharpe; Vijay K Kuchroo; Kimmie Ng; Marios Giannakis; Linda T Nieman; Genevieve M Boland; Andrew J Aguirre; Ana C Anderson; Orit Rozenblatt-Rosen; Aviv Regev; Nir Hacohen
Journal:  Cell       Date:  2021-08-26       Impact factor: 66.850

8.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Authors:  Lorenzo F Fanchi; Krijn K Dijkstra; José G Van den Berg; Emile E Voest; John B Haanen; Myriam Chalabi; Arend G Aalbers; Karolina Sikorska; Marta Lopez-Yurda; Cecile Grootscholten; Geerard L Beets; Petur Snaebjornsson; Monique Maas; Marjolijn Mertz; Vivien Veninga; Gergana Bounova; Annegien Broeks; Regina G Beets-Tan; Thomas R de Wijkerslooth; Anja U van Lent; Hendrik A Marsman; Elvira Nuijten; Niels F Kok; Maria Kuiper; Wieke H Verbeek; Marleen Kok; Monique E Van Leerdam; Ton N Schumacher
Journal:  Nat Med       Date:  2020-04-06       Impact factor: 53.440

Review 9.  Targeting metastatic cancer.

Authors:  Karuna Ganesh; Joan Massagué
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

10.  Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis.

Authors:  Semir Beyaz; Charlie Chung; Haiwei Mou; Khristian E Bauer-Rowe; Michael E Xifaras; Ilgin Ergin; Lenka Dohnalova; Moshe Biton; Karthik Shekhar; Onur Eskiocak; Katherine Papciak; Kadir Ozler; Mohammad Almeqdadi; Brian Yueh; Miriam Fein; Damodaran Annamalai; Eider Valle-Encinas; Aysegul Erdemir; Karoline Dogum; Vyom Shah; Aybuke Alici-Garipcan; Hannah V Meyer; Deniz M Özata; Eran Elinav; Alper Kucukural; Pawan Kumar; Jeremy P McAleer; James G Fox; Christoph A Thaiss; Aviv Regev; Jatin Roper; Stuart H Orkin; Ömer H Yilmaz
Journal:  Cell Stem Cell       Date:  2021-09-15       Impact factor: 25.269

  10 in total
  2 in total

1.  Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.

Authors:  Ranran Shi; Xiuman Zhou; Liwei Pang; Mingshuang Wang; Yubing Li; Chunxia Chen; Haoming Ning; Lihan Zhang; Guangxing Yue; Lu Qiu; Wenshan Zhao; Yuanming Qi; Yahong Wu; Yanfeng Gao
Journal:  Cancer Immunol Immunother       Date:  2022-10-17       Impact factor: 6.630

Review 2.  Tumor-Associated Neutrophils in Colorectal Cancer Development, Progression and Immunotherapy.

Authors:  Wei Zheng; Jingjing Wu; Yao Peng; Jing Sun; Pu Cheng; Qi Huang
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.